Palbociclib is processed as a crystalline free base with pH-dependent aqueous solubility, placing it in BCS Class II. For a 125 mg film-coated immediate-release tablet, direct compression is seldom employed because the API lot can exhibit poor flow and segregation when blended at high drug load. Instead, high-shear wet granulation is used to build dense granules that remain cohesive during compression. A representative internal development batch comprises 20–30% w/w palbociclib, 40–60% w/w mannitol or microcrystalline cellulose, 15–25% w/w pregelatinized starch, 2–4% w/w povidone K30, 2–5% w/w croscarmellose sodium, and 0.5–1.5% w/w magnesium stearate. The granulation endpoint is controlled by impeller power consumption rather than time alone. On a 25 L vertical granulator, an impeller speed of 100–200 rpm and chopper speed of 1500–3000 rpm with a 5–8 min wet massing window produce wet mass with a target torque rise of 3–6 N·m. Drying is performed in a fluid bed at an inlet air temperature of 50–70 °C until loss on drying is 1.5–3.0% w/w. The dried granules are milled through a 0.8 mm screen. Blending with croscarmellose sodium and magnesium stearate is carried out for 10–20 min at 15–25 rpm in a bin blender; the lubricant is added in a final 3 min pass. Compression on a rotary tablet press uses 4–8 kN precompression and 10–18 kN main compression, with tablet hardness held at 8–15 kp and friability below 0.8% w/w after 100 revolutions per USP <1216>. Dissolution is assessed by USP <711> Apparatus 2 at 37 °C and 50 rpm in 900 mL of pH 6.8 phosphate buffer containing 0.5% sodium lauryl sulfate; Q is not fixed in this overview but is set from clinical batch data. Related substances are controlled by HPLC per ICH Q3B. Residual solvents are controlled per ICH Q3C; elemental impurities per ICH Q3D. The film coating is applied as Opadry II at 3.0–4.0% weight gain. Coating parameters include inlet air temperature 60–75 °C, pan speed 4–8 rpm, spray rate 10–20 g/min/kg, and exhaust temperature 40–50 °C. The finished tablet is packaged in PVC/PVDC/aluminium blister cavities to limit moisture ingress. Palbociclib is classified as a hazardous drug, and NIOSH hazardous drug handling controls apply during all processing stages.

What Limits Palbociclib Capsule Fill Weight Uniformity at Low-Dose Strengths?

Commercial oral capsules of palbociclib are marketed as 75 mg, 100 mg, and 125 mg strengths in hard gelatin or HPMC shells. The capsule fill blend is typically composed of palbociclib, lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, and magnesium stearate; published quantitative formula details remain limited. Fill weight uniformity is directly constrained by the 75 mg strength because the API-to-excipient ratio and the absolute fill mass determine the sensitivity of the tamping pin volumetric process to powder bed porosity. A change of 1% w/w in bulk density can produce a fill weight deviation outside the acceptance limits of USP <905> if the fill weight is below approximately 200 mg. For this reason, the blend is generally dry granulated by roller compaction or densified through a low-shear preblend to achieve a Carr index below 25% and an angle of repose below 40°. On a tamping pin capsule filler operating at 25,000–75,000 capsules per hour, the powder bed is maintained at 70–85% of the hopper working volume. The dosing disc thickness is selected to deliver 150–350 mg fill mass. In-process control uses an automatic checkweigher with a sampling interval of 10–15 min and an action limit of ±3% of target. Environmental relative humidity is held at 40–50% RH because hard gelatin shells require 13–16% water activity for mechanical resilience; lower RH increases shell brittleness and higher RH promotes sticking. The API is jet-milled to a laser diffraction D90 below 10 µm per USP <429> before blending. The finished capsule is tested for dissolution using a method similar to that described for tablets; however, sink conditions may require higher surfactant concentrations because of the slower disintegration of the shell in low-pH media. Finished capsules are packaged in HDPE bottles with desiccant. Palbociclib capsules should not be opened or crushed; NIOSH hazardous drug handling controls apply.

For patients who cannot swallow capsules, a granule intermediate for sachet or stick-pack presentation is manufactured by fluid-bed top-spray granulation. A typical prototype batch is initiated from a dry blend of 20–30% w/w palbociclib, 50–65% w/w lactose monohydrate or mannitol, 10–20% w/w pregelatinized starch, and 2–5% w/w croscarmellose sodium. A 5–10% w/w aqueous povidone K90 solution is sprayed at 10–20 g/min/kg dry charge; inlet air temperature is maintained at 60–70 °C and product temperature at 30–38 °C. Atomizing air pressure is held at 2.0–3.0 bar. Filter shaking is set to 5 s every 30 s to avoid fines loss. The granulation endpoint is 1.5–2.5% w/w loss on drying. Dried granules are sieved through a 0.5 mm screen and the fraction between 150 µm and 500 µm is retained for filling. Fines below 90 µm are recycled only if they do not exceed 15% of total granule mass; excess fines can cause sachet dusting and dose non-uniformity. The granules are filled into cold-form aluminium or polyester/aluminium/LLDPE sachet stock using a vertical form-fill-seal machine. Fill weight is verified by gravimetric statistical sampling every 15 min. Moisture barrier is critical because palbociclib has limited aqueous solubility and any surface amorphous conversion during wet granulation can reduce dissolution. The sachet product is tested for water content by Karl Fischer titration, with an action limit of <2.0% w/w. Dissolution is determined using USP <711> Apparatus 2 at 50 rpm. If the granules are intended for enteral administration, the product must be flushed through a size 8 French nasogastric tube with 20 mL purified water. The terminal finished form is a unit-dose oral granule or sachet for reconstitution in water or as a sprinkle dose. Bioequivalence to the capsule formulation cannot be assumed and must be established through a regulated clinical study.

Vial Processing Windows for Freeze-Dried Palbociclib Injection

Palbociclib free base is not freely water-soluble; parenteral presentations therefore require a solubility-enabling strategy such as acidic pH adjustment, co-solvent addition, or cyclodextrin complexation. No compendial monograph for palbociclib injection is listed in USP 43–NF 38 or Ph. Eur. 11.0 at time of writing; published data for a specific lyophilized formulation are limited. In a development model, a 10 mg per vial freeze-dried unit can be prepared from a pre-lyophilization solution containing palbociclib 1–5 mg/mL, sulfobutylether-β-cyclodextrin 10–30% w/v, citric acid/sodium citrate buffer 10–50 mM, and mannitol or trehalose 2–5% w/v as cryoprotectant. The solution is filtered through a 0.2 µm PVDF membrane at 0.5–1.0 bar differential pressure. Filling into 10 mL Type I borosilicate glass vials is performed under nitrogen overlay to limit oxidation. Lyophilization cycle parameters include freezing at -45 °C for 2 h; primary drying at -20 °C to -10 °C shelf temperature and 100–200 mTorr for 20–30 h; secondary drying at 35 °C for 4–6 h until residual moisture by Karl Fischer is <1.0% w/w. The cake mass and reconstitution time are recorded. Reconstitution with 5 mL water for injection should yield a clear to slightly opalescent solution within 3 min. Product is tested for particulate matter per USP <788>, sterility per USP <71>, bacterial endotoxins per USP <85>, uniformity of dosage units per USP <905>, and visible particulates per USP <790>. The injection must be administered by a licensed professional; the formulation must not be considered a substitute for oral palbociclib without clinical equivalence data.

When Palbociclib Oral Suspension Is Prepared from a Dedicated Granule Intermediate in a Controlled Setting

Palbociclib is classified as a hazardous drug and capsule contents must not be crushed or opened at the point of care. If a dedicated granule intermediate is authorized for suspension, it is reconstituted in a child-resistant amber oral dispenser using purified water or a suspending vehicle containing hypromellose and carboxymethylcellulose sodium. A target concentration of 5 mg/mL is practical for 75–125 mg oral doses. The vehicle is added in two stages with intermittent shaking to achieve a homogeneous suspension. The in-use beyond-use date is assigned according to USP <795>. For an aqueous oral suspension stored under refrigeration at 2–8 °C, the default beyond-use date is 14 days unless a bracketed stability study supports a longer interval. Photostability is controlled with amber polyethylene terephthalate packaging. Light protection follows ICH Q1B if photostability data indicate sensitivity. Dose measurement requires a calibrated oral syringe marked in 0.5 mL increments. Viscosity of the vehicle is controlled to 50–200 mPa·s at 25 °C; high viscosity can cause measurable retention in the syringe tip. The granule particle size must be below 200 µm for uniform wetting and rapid dispersion. Larger granules settle too quickly and create dose non-uniformity. The prepared suspension is not bioequivalent to the capsule unless comparative pharmacokinetic data are available from a regulatory filing. Cleaning verification for compounding equipment follows USP <800> hazardous drug standards.

Development of amorphous solid dispersion intermediates is evaluated when dissolution-rate-limited absorption is observed in pilot bioavailability studies. Hot-melt extrusion of palbociclib with vinylpyrrolidone-vinyl acetate copolymer or hypromellose acetate succinate at a drug load of 15–30% w/w produces a single-phase amorphous extrudate when processed at 150–180 °C and 50–150 rpm screw speed on a co-rotating twin-screw extruder with an L/D ratio of 40:1. The extrudate is milled through a 0.5 mm screen and blended with mannitol, croscarmellose sodium, and magnesium stearate before compression. Residual crystallinity is checked by powder X-ray diffraction per USP <941>. An amorphous halo without characteristic crystalline reflections is required to confirm conversion. The glass transition temperature of the extrudate is measured by differential scanning calorimetry at 10 °C/min heating rate. The value depends on the polymer ratio and would be expected above 80 °C to reduce the risk of recrystallization during storage at 25 °C/60% RH. Initial dissolution profiles must be generated batch-by-batch because the release rate depends on drug loading and polymer grade; published data specific to palbociclib hot-melt extrudates are limited. The finished tablet retains the solid-dispersion intermediate as the internal blend. Drug product stability is assigned under ICH Q1A(R2) conditions with 6-month accelerated testing. This process is not applied to the currently marketed capsule formulation but is a technical pathway for differentiated tablet products.